237 related articles for article (PubMed ID: 36721777)
21. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
22. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
23. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
24. Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
Lapke N; Chen CH; Chang TC; Chao A; Lu YJ; Lai CH; Tan KT; Chen HC; Lu HY; Chen SJ
BMC Cancer; 2021 May; 21(1):499. PubMed ID: 33947352
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
[TBL] [Abstract][Full Text] [Related]
27. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
[No Abstract] [Full Text] [Related]
28. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Fujiwara S
Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
[TBL] [Abstract][Full Text] [Related]
29. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
30. Evolving population-based statistics for rare epithelial ovarian cancers.
Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
[TBL] [Abstract][Full Text] [Related]
31. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
Prat J; D'Angelo E; Espinosa I
Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
[TBL] [Abstract][Full Text] [Related]
32. Distinguishing the progression of an endometrioma: Benign or malignant?
Bastu E; Onder S; Demiral I; Ozsurmeli M; Keskin G; Takmaz O; Ozaltin S; Gorgen H; Gungor M; Yavuz E; Buyru F
Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():79-84. PubMed ID: 30245441
[TBL] [Abstract][Full Text] [Related]
33. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
34. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Accuracy of Alpha-Methylacyl-CoA Racemase Immunohistochemical Expression for the Diagnosis of Ovarian and Endometrial Clear Cell Carcinomas.
Nili F; Fathi S; Tavakoli M; Mirzaian E; Lotfi M
Iran J Pathol; 2023; 18(1):57-63. PubMed ID: 37383161
[TBL] [Abstract][Full Text] [Related]
37. Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis.
Nomura S; Watanabe T; Honma R; Matsukura S; Ito E; Imai JI; Kiko Y; Suzuki O; Hashimoto Y; Kojima M; Furukawa S; Soeda S; Watanabe S; Fujimori K
Fukushima J Med Sci; 2024 Apr; 70(2):65-73. PubMed ID: 38494731
[TBL] [Abstract][Full Text] [Related]
38. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Kuroda T; Kohno T
Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
[TBL] [Abstract][Full Text] [Related]
39. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
40. Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma.
Ju B; Wang J; Yang B; Sun L; Guo Y; Hao Q; Wu J
Int J Gynecol Pathol; 2018 Jul; 37(4):388-396. PubMed ID: 28796747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
